share_log

Novavax | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-BlackRock, Inc.(7.1%)

SEC announcement ·  Jan 26 22:25
Summary by Moomoo AI
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a 7.1% ownership stake in Novavax Inc., a biotechnology company specializing in vaccine development. The filing, which is the fourth amendment, shows that BlackRock has sole voting power over 8,323,116 shares and sole dispositive power over 8,436,179 shares of Novavax's common stock. This position by BlackRock does not aim to change or influence the control of Novavax. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
On December 31, 2023, BlackRock, Inc., a Delaware-based investment management corporation, filed an amended Schedule 13G with the Securities and Exchange Commission (SEC), indicating a 7.1% ownership stake in Novavax Inc., a biotechnology company specializing in vaccine development. The filing, which is the fourth amendment, shows that BlackRock has sole voting power over 8,323,116 shares and sole dispositive power over 8,436,179 shares of Novavax's common stock. This position by BlackRock does not aim to change or influence the control of Novavax. The filing was certified by Spencer Fleming, Attorney-In-Fact for BlackRock, Inc., on January 26, 2024.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more